Pharmacotherapy for Acute Respiratory Distress Syndrome
Authors:
- 2 October 2012
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 32 (10) , 943-957
Abstract
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) represent a continuum of a clinical syndrome of respiratory failure due to refractory hypoxia. Acute respiratory distress syndrome is differentiated from ALI by a greater degree of hypoxemia and is associated with higher morbidity and mortality. The mortality for ARDS ranges from 22–41%, with survivors usually requiring long‐term rehabilitation to regain normal physiologic function. Numerous pharmacologic therapies have been studied for prevention and treatment of ARDS; however, studies demonstrating clear clinical benefit for ARDS‐related mortality and morbidity are limited. In this focused review, controversial pharmacologic therapies that have demonstrated, at minimum, a modest clinical benefit are discussed. Three pharmacologic treatment strategies are reviewed in detail: corticosteroids, fluid management, and neuromuscular blocking agents. Use of corticosteroids to attenuate inflammation remains controversial. Available evidence does not support early administration of corticosteroids. Additionally, administration after 14 days of disease onset is strongly discouraged. A liberal fluid strategy during the early phase of comorbid septic shock, balanced with a conservative fluid strategy in patients with ALI or ARDS during the postresuscitation phase, is the optimum approach for fluid management. Available evidence supports an early, short course of continuous‐infusion cisatracurium in patients presenting with severe ARDS. Evidence of safe and effective pharmacologic therapies for ARDS is limited, and clinicians must be knowledgeable about the areas of controversies to determine application to patient care.Keywords
This publication has 60 references indexed in Scilit:
- Functional Disability 5 Years after Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2011
- Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trialThe Lancet, 2009
- Risk factors for the development of acute lung injury in patients with septic shock: An observational cohort study*Critical Care Medicine, 2008
- Effect of mechanical ventilation in the prone position on clinical outcomes in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysisCanadian Medical Association Journal, 2008
- Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome*Critical Care Medicine, 2008
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsisCritical Care Medicine, 2000
- Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordinationIntensive Care Medicine, 1994
- High-Dose Corticosteroids in Patients with the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1987
- The Effects of High-Dose Corticosteroids in Patients with Septic ShockNew England Journal of Medicine, 1984